Data / Drug companies / AbbVie Deutschland GmbH & Co Kg
AbbVie Deutschland GmbH & Co Kg: 11 products in the FDA NDC directory, labeler code 12613
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
AbbVie Deutschland GmbH & Co Kg (labeler code 12613) lists 11 products in the FDA National Drug Code Directory. By type: 11 drugs for further processing. Its main marketing category is drugs for further processing. The newest product started marketing on June 17, 2025.
The request: Watch AbbVie Deutschland GmbH & Co Kg (FDA labeler code 12613): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 12613
- Products in commercial distribution
- 11
- Packages
- 11
- Finished drugs by generic name
- 0
- Prescription products
- 0
- Over the counter products
- 0
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- May 6, 2010
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Drugs for further processing | 11 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Drugs for further processing | 11 | 100% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 7 | 63.6% |
| Pellet | 2 | 18.2% |
| Tablet | 2 | 18.2% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Glecaprevir | 12613-3048 | Pellet | Drugs for further processing | June 17, 2025 |
| Pibrentasvir | 12613-3049 | Pellet | Drugs for further processing | June 13, 2025 |
| Lopinavir and ritonavir | 12613-3008 | Tablet, film coated | Drugs for further processing | November 15, 2023 |
| Lopinavir and ritonavir | 12613-4014 | Tablet, film coated | Drugs for further processing | October 27, 2023 |
| Glecaprevir cv pibrentasvir | 12613-2625 | Tablet, film coated | Drugs for further processing | November 29, 2022 |
| Ritonavir | 12613-2340 | Tablet, film coated | Drugs for further processing | August 2, 2022 |
| Lopinavir and ritonavir | 12613-2605 | Tablet | Drugs for further processing | April 8, 2020 |
| Lopinavir and ritonavir | 12613-1575 | Tablet | Drugs for further processing | April 8, 2020 |
| Lopinavir and ritonavir | 12613-6799 | Tablet, film coated | Drugs for further processing | June 18, 2010 |
| Lopinavir and ritonavir | 12613-0522 | Tablet, film coated | Drugs for further processing | June 18, 2010 |
| Ritonavir | 12613-3333 | Tablet, film coated | Drugs for further processing | May 6, 2010 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.